מינוי Plus

התחברות ל-baba News

חשבון אחד לאתר, לאייפון ולאנדרואיד — המנוי נשאר איתכם.

או קוד במייל

חיפוש סיפורים

הקלידו לפחות שני תווים. התוצאות מגיעות מכל המערכות ש-baba קורא.

↑↓ למעבר · ↵ לפתיחה · esc לסגירה

התחברות ל-baba News

התחברו כדי להמשיך לשאול. News Plus מסיר את המגבלה היומית.

או קוד במייל

ידיעה מתמשכת· היום

Obesity Drug Wegovy Shows Promise in Young Children in New Study

2 התפתחויות

Hamalבריאות

Weight-Loss Drug Wegovy Tested Successfully in Children as Young as Six

תומצת מתוך Hamal על ידי baba

מרכזטון ענייני

עברית · מערכת חדשות אחת

The weight-loss drug Wegovy has demonstrated significant success in a clinical trial for children aged six to twelve with obesity, with nearly 80% achieving a 10% BMI reduction. The trial, conducted by Novo Nordisk, also showed improvements in cardiac and metabolic health markers. While the drug's safety profile appears similar to previous studies, long-term effects are still under investigation. In Israel, the drug is currently approved only for adolescents aged 12 and older.

הידיעה ב-5 שורות · תקציר של baba

  • Wegovy trial shows nearly 80% of children aged 6-12 with obesity achieved 10% BMI reduction.
  • The drug also improved cardiac and metabolic health markers in pediatric participants.
  • Novo Nordisk reported a similar safety profile to previous semaglutide studies.
  • In Israel, Wegovy is approved for adolescents 12 and older, not younger children.
  • Long-term effects and sustained weight loss after treatment cessation require further study.

The weight-loss injection Wegovy, already approved for adults and adolescents, has shown promising results in a clinical trial involving children aged six to under twelve with obesity. According to manufacturer Novo Nordisk, nearly 80% of children receiving the drug achieved at least a 10% reduction in their Body Mass Index (BMI), compared to none in the placebo group. This metric refers to BMI reduction, not necessarily a 10% decrease in body weight.

The STEP Young trial, which involved children with severe obesity at the outset, administered weekly injections of semaglutide, the active ingredient in Wegovy, or a placebo. Both groups also received counseling on reduced-calorie diets and increased physical activity. After 68 weeks, the Wegovy group saw an average BMI decrease of 17.4%, while the placebo group experienced a 2.2% increase.

Further analysis indicated that 38.4% of children in the Wegovy group dropped below the obesity threshold, compared to 2.1% in the placebo group. The drug's safety profile in the trial was similar to previous studies, with no unexpected safety signals regarding growth or sexual development. However, long-term effects and sustained weight loss after treatment cessation require further investigation.

Dr. Anya Gesterboff, Director of the Yale University Obesity Research Center, noted that severe obesity can impact children's health and daily lives, and the treatment also showed improvements in cardiac and metabolic health markers. While these improvements are encouraging, they do not yet confirm the prevention of long-term complications.

In Israel, Wegovy is currently approved for adolescents aged 12 and above under specific conditions, including a weight requirement and accompanying medical and nutritional support. The trial results for younger children do not constitute approval for their use, which awaits regulatory bodies like the FDA.

Hamalמרכז · תל אביב

התחברות ל-baba News

התחברו כדי לעקוב אחרי מערכות, נושאים ואנשים.

או קוד במייל

בריאותנושא

התחברות ל-baba News

התחברו כדי לעקוב אחרי מערכות, נושאים ואנשים.

או קוד במייל

מוזכרים

ידיעות קשורות · 1

לא אותו אירוע: ידיעות אחרות שחולקות עם הידיעה הזו אנשים, מקומות או נושא. רקע, תגובות והמשכים.

פתיחת המבזקים